Category Archives: Pharmaceuticals

Global outlook for biotech IPOs looks bright; will “precision” and “convergence” be the new mantras?

Many investors typically start the New Year searching for prescient predictions. Armed with a raft of “foolproof” data they then take an oath to stick with new, rock-solid resolutions, usually,… Read more »

Drugs that may shape 2017 and the trends molding new-drug discovery

Here’s a look at the drugs that may shape 2017, compliments of FirstWord Pharma. It’s a list of some of the products I agree are likely to dominate industry news… Read more »

Valeant divests assets worth $2.1 billion to ease debt load; finally a smart move, but too little, too late?

Valeant Pharmaceuticals International Inc. (Laval Quebec) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than… Read more »

Trump scorns Pharma, calls for drug pricebidding; stocks swoon on latest pivot, but does the POTUS-elect mean it?

President-elect Donald Trump on Wednesday (January 11, 2017) pledged to change the way the federal government purchases prescription drugs, a striking, largely unforseen warning to the drug industry that he… Read more »

Japan’s Takeda leads off 2017 M&A season with gutsy deal to buy US cancer specialist Ariad for $5.2 billion; it’s expensive, but probably worth it

Japan’s Takeda Pharmaceutical Co. Ltd. agreed to acquire Ariad Pharmaceuticals Inc. (Cambridge MA) for $24 per share in cash, or an enterprise value of approximately $5.2 billion, boosting its oncology… Read more »

Biotech predictions for 2017 return to positive fundamentals; 2016 meltdown still in rear-view mirror

The NASDAQ Biotech Index got hammered in 2016–-but mostly due to the market melting in January 2016. The Nasdaq Biotech Index collapsed 28% in the opening weeks of 2016 and… Read more »

Gilead starts 2017 by snatching Novartis cancer specialist; a harbinger of early (and ferocious) M&A?

Gilead Sciences Inc. (Foster City CA) has poached a top cancer specialist from Swiss drugmaker Novartis AG (Basel) as the US healthcare group sharpens its focus on oncology. Alessandro Riva… Read more »

Novo Nordisk to cap price increases as drug costs face more scrutiny; do two drugmakers equal a trend?

With drug companies under fire over prices, the world’s largest insulin maker plans to limit increases and join competitors by introducing a model that ties the cost of medicines to… Read more »

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky

Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »

Juno Therapeutics halts study after more patient deaths; shares crash

Juno Therapeutics Inc.’s (Seattle WA) shares plunged 23% last week after the biopharmaceutical company voluntarily placed a mid-stage clinical trial on hold after two patients suffered cerebral edema earlier in the… Read more »